How the coronavirus pandemic may affect cancer clinical trials
In this article published in Cancer Therapy Advisor this week, [...]
ESMO Virtual 2020: Circulating tumour DNA in metastatic kidney cancer patients
In a paper presented at this year’s European Society of [...]
ESMO Virtual 2020: Biomarker-guided therapy in metastatic kidney cancer
Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were [...]
ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer
At the European Society of Medical Oncology (ESMO) Virtual Congress [...]
ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer
Non-clear cell renal cell carcinoma (RCC) accounts for about 25% [...]
ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer
At the European Society of Medical Oncology (ESMO) Virtual Congress [...]
PBRM1 as a biomarker for kidney cancer
In this video interview, Dr Eric Jonasch from MD Anderson [...]
ESMO Virtual 2020: Treatment-free survival after immunotherapy vs. targeted therapy for advanced kidney cancer
Over the past 2 years, the use of combination therapies [...]
ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer
Over the past 2 years, the use of combination therapies [...]
Sapanisertib is tolerable and shows activity in advanced kidney cancer
In a phase I study to look at the safety [...]
